

Advent France Biotechnology appoints Sidonie Fabre as CFO

- **Sidonie Fabre's extensive career in finance will help Advent France Biotechnology (AFB) strengthen financial structure - as growing VC firm**

Paris, France, June 8, 2021 – Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the appointment of Sidonie Fabre, as chief financial officer. Sidonie took up her role on June 1.

Sidonie Fabre's career history as CFO spans 15 years in the investment field, for listed and private companies. She was previously CFO at Crédit Agricole Régions Investissement. Sidonie started her career in finance as a sell-side analyst at CM-CIC Securities then as an asset manager at Covea Finance, before moving to a court-appointed administrator as a receivership director. Sidonie previously worked as a business development manager in the engineering industry from 2012 to 2016. She holds a master's degree in finance from Paris Dauphine University (Paris, France).

"I'm delighted to join AFB and its experienced team of investment experts. I'm truly fascinated by the biotech industry and its innovative startups. This is an exciting time for AFB and I'm very happy to help the company achieve its growth goals during 2021 and beyond," said Sidonie Fabre.

As CFO at AFB, Sidonie will oversee all financial activities for the company. One of her priorities will include bringing a new vision for the company's financial structure and providing a range of innovative solutions – which includes improving the reporting process to Limited Partners and legal authorities. She will also participate in promoting AFB to institutional investors.

"Sidonie is a multi-talented expert in business, financial and legal issues and we are thrilled to welcome her to the AFB team. Our continued growth requires stronger financial organization and management; Sidonie will help us achieve that as we are preparing to raise our second fund", said Alain Huriez, MD, AFB co-founder and chairman.

About Advent France Biotechnology

Advent France Biotechnology (AFB) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AFB partners' unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company's growth. Created in 2016, AFB partners has made several European investments in France, Belgium, Spain and Ireland. AFB partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is managed by Alain Huriez and Matthieu Coutet. It has appointed a number of investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise. AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund

for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.

www.adventfb.com

Press and Analyst Contacts

Andrew Lloyd & Associates

Celine Gonzalez / Amanda Bown

celine@ala.com – amanda@ala.com

Tel.: +44 1275 675 100

@ALA_Group
